Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.71 |
| ▸ | KRAS | P01116 | 4/20 | 0.50 |
| ▸ | PRNP | P04156 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318332 | 0.88 | PTGDR2 (0.90) | PTGDR2PTGS1CYP2C19CYP2C9SLC6A4 | |
| SCHEMBL316839 | 0.84 | PTGDR2 (0.65) | PTGDR2PTGS1KRASCYP2C19CYP2C9 | |
| SCHEMBL318105 | 0.83 | PTGDR2 (0.61) | PTGDR2PTGS1KRASPRNPPOLB | |
| SCHEMBL318388 | 0.82 | PTGDR2 (0.83) | PTGDR2PTGS1CYP2C19CYP2C9SLC6A4 | |
| SCHEMBL317806 | 0.82 | PTGDR2 (0.59) | PTGDR2PTGS1KRASPRNPPOLB | |
| SCHEMBL6247326 | 0.82 | PTGDR2 (0.59) | PTGDR2PTGS1KRASCYP2C19CYP2C9 | |
| SCHEMBL318694 | 0.82 | PTGDR2 (0.81) | PTGDR2PTGS1CYP2C19CYP2C9SLC6A4 | |
| SCHEMBL316988 | 0.81 | PTGDR2 (0.61) | PTGDR2PTGS1KRASPOLBRXFP1 | |
| SCHEMBL317810 | 0.81 | PTGDR2 (0.76) | PTGDR2PTGS1CYP2C19CYP2C9SLC6A4 | |
| SCHEMBL317473 | 0.80 | PTGDR2 (0.70) | PTGDR2PTGS1PRNPRXFP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093278-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20100210685-A1 | Novel Substituted Indoles | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7754735-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210685-A1 | Novel Substituted Indoles | IDO1, IDO2, TPH1 | PTGDR2 429/4885PTGS1 413/4885KRAS 3021/4885 |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | PTGDR2 54/4885PTGS1 191/4885KRAS 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.